N
PTCT icon

Natixis’s PTC Therapeutics PTCT Stock Holding History

Natixis’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$1.25M – 1301
2022
Q3 		$1.25M Buy
+25,000
New +$1.22M 0.01% 710
2021
Q4 		– Sell
-113,000
Closed -$4.21M – 1324
2021
Q3 		$4.21M Sell
113,000
-97,892
-46% -$4.02M 0.01% 583
2021
Q2 		$8.91M Hold
210,892
– – 0.04% 296
2021
Q1 		$9.99M Buy
+210,892
New +$12.5M 0.03% 376

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Natixis's PTCT Position: Q4 2022 in Review

Natixis sold out of PTC Therapeutics (PTCT) in Q4 2022, closing a stake of 25,000 shares — an estimated $1.25M sold.

Natixis first reported a position in PTCT in Q1 2021 and held it in 4 quarters. The position peaked at $9.99M in Q1 2021. 202 funds tracked by Wall St. Rank hold PTCT as of Q4 2022.

  • Natixis reported no remaining PTC Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Natixis sold 25,000 PTC Therapeutics shares in Q4 2022, an estimated $1.25M.
  • Natixis first reported a position in PTC Therapeutics in Q1 2021 and held it in 4 quarters.
  • Natixis's PTC Therapeutics position peaked at $9.99M in Q1 2021.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2022.

Based on Natixis's 13F filing for Q4 2022, filed 13 Feb 2023.